You are reading 1 of 2 free-access articles allowed for 30 days
Totality of trials data confirm Tamiflu reduces length of symptoms, complications, and hospital admissions from influenza.
The journal says this is the most thorough analysis of oseltamivir (marketed as Tamiflu) data to date, including all available published and unpublished randomised treatment trials of adults,
For the first time, the meta-analysis includes individual patient data from all published and unpublished trials.
The study was conducted by an independent research group led by Arnold Monto, Professor of Epidemiology at the University of Michigan School of Public Health, USA, and Stuart Pocock, Professor of Medical Statistics at the London School of Hygiene & Tropical Medicine, UK.
“The safety and effectiveness of oseltamivir has been hotly debated, with some researchers claiming there is little evidence that oseltamivir works,” said Mr Arnold Monto.
“Our meta-analysis provides compelling evidence that oseltamivir therapy reduces by one day the typical length of illness in adults infected with influenza and also prevents complications and reduces the number of people needing hospital treatment.
“Whether the magnitude of these benefits outweigh the harms of nausea and vomiting needs careful consideration.”
For full Article see www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62449-1/abstract